Global Human Rabies Immunoglobulin (IM) Sales 麻豆原创 Report 2023

Publication ID:

PB501234092

Publication Date:

January 3, 2023

Pages:

127

Publisher:

MRRPB5

Countries:

Global [1]

USD 4,000.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure.

Figure Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient's passive immunization.

In this report, we study ERIG (Equine Rabies Immunoglobulin) and HRIG (Human Rabies Immunoglobulin)
麻豆原创 Analysis and Insights: Global Human Rabies Immunoglobulin (IM) 麻豆原创
Due to the COVID-19 pandemic, the global Human Rabies Immunoglobulin (IM) market size is estimated to be worth US$ 396 million in 2022 and is forecast to a readjusted size of US$ 606.3 million by 2029 with a CAGR of 6.2% during the forecast period 2023-2029. Fully considering the economic change by this health crisis, ERIG accounting for % of the Human Rabies Immunoglobulin (IM) global market in 2022, is projected to value US$ million by 2029, growing at a revised % CAGR from 2023 to 2029. While Category II Exposure segment is altered to an % CAGR throughout this forecast period.
Global Human Rabies Immunoglobulin (IM) key players include CSL Behring, Grifols, Sanofi, etc. Global top three manufacturers hold a share about 60%.
North America is the largest market, with a share over 30%, followed by China and Europe, both have a share about 45 percent.
In terms of product, HRIG is the largest segment, with a share over 85%. And in terms of application, the largest application is Category III Exposure, followed by Category II Exposure.
Global Human Rabies Immunoglobulin (IM) Scope and 麻豆原创 Size
The global Human Rabies Immunoglobulin (IM) market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Human Rabies Immunoglobulin (IM) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2029.
Segment by Type
ERIG
HRIG
Segment by Application
Category II Exposure
Category III Exposure
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
CSL Behring
Grifols
Sanofi
Sichuan Yuanda Shuyang
CNBG
Kamada
CBPO
Shuanglin Bio
Weiguang Bio
Shanghai RAAS
Bharat Serum
VINS

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Human Rabies Immunoglobulin (IM) 麻豆原创 Overview
1.1 Human Rabies Immunoglobulin (IM) Product Scope
1.2 Human Rabies Immunoglobulin (IM) Segment by Type
1.2.1 Global Human Rabies Immunoglobulin (IM) Sales by Type (2018 & 2022 & 2029)
1.2.2 ERIG
1.2.3 HRIG
1.3 Human Rabies Immunoglobulin (IM) Segment by Application
1.3.1 Global Human Rabies Immunoglobulin (IM) Sales Comparison by Application (2018 & 2022 & 2029)
1.3.2 Category II Exposure
1.3.3 Category III Exposure
1.4 Human Rabies Immunoglobulin (IM) 麻豆原创 Estimates and Forecasts (2018-2029)
1.4.1 Global Human Rabies Immunoglobulin (IM) 麻豆原创 Size in Value Growth Rate (2018-2029)
1.4.2 Global Human Rabies Immunoglobulin (IM) 麻豆原创 Size in Volume Growth Rate (2018-2029)
1.4.3 Global Human Rabies Immunoglobulin (IM) Price Trends (2018-2029)
2 Human Rabies Immunoglobulin (IM) Estimates and Forecasts by Region
2.1 Global Human Rabies Immunoglobulin (IM) 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2 Global Human Rabies Immunoglobulin (IM) Retrospective 麻豆原创 Scenario by Region (2018-2023)
2.2.1 Global Human Rabies Immunoglobulin (IM) Sales 麻豆原创 Share by Region (2018-2023)
2.2.2 Global Human Rabies Immunoglobulin (IM) Revenue 麻豆原创 Share by Region (2018-2023)
2.3 Global Human Rabies Immunoglobulin (IM) 麻豆原创 Estimates and Forecasts by Region (2024-2029)
2.3.1 Global Human Rabies Immunoglobulin (IM) Sales Estimates and Forecasts by Region (2024-2029)
2.3.2 Global Human Rabies Immunoglobulin (IM) Revenue Forecast by Region (2024-2029)
2.4 Geographic 麻豆原创 Analysis: 麻豆原创 Facts & Figures
2.4.1 United States Human Rabies Immunoglobulin (IM) Estimates and Projections (2018-2029)
2.4.2 Europe Human Rabies Immunoglobulin (IM) Estimates and Projections (2018-2029)
2.4.3 China Human Rabies Immunoglobulin (IM) Estimates and Projections (2018-2029)
2.4.4 Japan Human Rabies Immunoglobulin (IM) Estimates and Projections (2018-2029)
2.4.5 Southeast Asia Human Rabies Immunoglobulin (IM) Estimates and Projections (2018-2029)
2.4.6 India Human Rabies Immunoglobulin (IM) Estimates and Projections (2018-2029)
3 Global Human Rabies Immunoglobulin (IM) Competition Landscape by Players
3.1 Global Top Human Rabies Immunoglobulin (IM) Players by Sales (2018-2023)
3.2 Global Top Human Rabies Immunoglobulin (IM) Players by Revenue (2018-2023)
3.3 Global Human Rabies Immunoglobulin (IM) 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Human Rabies Immunoglobulin (IM) as of 2022)
3.4 Global Human Rabies Immunoglobulin (IM) Average Price by Company (2018-2023)
3.5 Manufacturers Human Rabies Immunoglobulin (IM) Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Human Rabies Immunoglobulin (IM) 麻豆原创 Size by Type
4.1 Global Human Rabies Immunoglobulin (IM) Historic 麻豆原创 Review by Type (2018-2023)
4.1.1 Global Human Rabies Immunoglobulin (IM) Sales by Type (2018-2023)
4.1.2 Global Human Rabies Immunoglobulin (IM) Revenue by Type (2018-2023)
4.1.3 Global Human Rabies Immunoglobulin (IM) Price by Type (2018-2023)
4.2 Global Human Rabies Immunoglobulin (IM) 麻豆原创 Estimates and Forecasts by Type (2024-2029)
4.2.1 Global Human Rabies Immunoglobulin (IM) Sales Forecast by Type (2024-2029)
4.2.2 Global Human Rabies Immunoglobulin (IM) Revenue Forecast by Type (2024-2029)
4.2.3 Global Human Rabies Immunoglobulin (IM) Price Forecast by Type (2024-2029)
5 Global Human Rabies Immunoglobulin (IM) 麻豆原创 Size by Application
5.1 Global Human Rabies Immunoglobulin (IM) Historic 麻豆原创 Review by Application (2018-2023)
5.1.1 Global Human Rabies Immunoglobulin (IM) Sales by Application (2018-2023)
5.1.2 Global Human Rabies Immunoglobulin (IM) Revenue by Application (2018-2023)
5.1.3 Global Human Rabies Immunoglobulin (IM) Price by Application (2018-2023)
5.2 Global Human Rabies Immunoglobulin (IM) 麻豆原创 Estimates and Forecasts by Application (2024-2029)
5.2.1 Global Human Rabies Immunoglobulin (IM) Sales Forecast by Application (2024-2029)
5.2.2 Global Human Rabies Immunoglobulin (IM) Revenue Forecast by Application (2024-2029)
5.2.3 Global Human Rabies Immunoglobulin (IM) Price Forecast by Application (2024-2029)
6 United States Human Rabies Immunoglobulin (IM) 麻豆原创 Facts & Figures
6.1 United States Human Rabies Immunoglobulin (IM) Sales by Company
6.1.1 United States Human Rabies Immunoglobulin (IM) Sales by Company (2018-2023)
6.1.2 United States Human Rabies Immunoglobulin (IM) Revenue by Company (2018-2023)
6.2 United States Human Rabies Immunoglobulin (IM) Sales Breakdown by Type
6.2.1 United States Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2018-2023)
6.2.2 United States Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2024-2029)
6.3 United States Human Rabies Immunoglobulin (IM) Sales Breakdown by Application
6.3.1 United States Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2018-2023)
6.3.2 United States Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2024-2029)
7 Europe Human Rabies Immunoglobulin (IM) 麻豆原创 Facts & Figures
7.1 Europe Human Rabies Immunoglobulin (IM) Sales by Company
7.1.1 Europe Human Rabies Immunoglobulin (IM) Sales by Company (2018-2023)
7.1.2 Europe Human Rabies Immunoglobulin (IM) Revenue by Company (2018-2023)
7.2 Europe Human Rabies Immunoglobulin (IM) Sales Breakdown by Type
7.2.1 Europe Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2018-2023)
7.2.2 Europe Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2024-2029)
7.3 Europe Human Rabies Immunoglobulin (IM) Sales Breakdown by Application
7.3.1 Europe Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2018-2023)
7.3.2 Europe Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2024-2029)
8 China Human Rabies Immunoglobulin (IM) 麻豆原创 Facts & Figures
8.1 China Human Rabies Immunoglobulin (IM) Sales by Company
8.1.1 China Human Rabies Immunoglobulin (IM) Sales by Company (2018-2023)
8.1.2 China Human Rabies Immunoglobulin (IM) Revenue by Company (2018-2023)
8.2 China Human Rabies Immunoglobulin (IM) Sales Breakdown by Type
8.2.1 China Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2018-2023)
8.2.2 China Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2024-2029)
8.3 China Human Rabies Immunoglobulin (IM) Sales Breakdown by Application
8.3.1 China Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2018-2023)
8.3.2 China Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2024-2029)
9 Japan Human Rabies Immunoglobulin (IM) 麻豆原创 Facts & Figures
9.1 Japan Human Rabies Immunoglobulin (IM) Sales by Company
9.1.1 Japan Human Rabies Immunoglobulin (IM) Sales by Company (2018-2023)
9.1.2 Japan Human Rabies Immunoglobulin (IM) Revenue by Company (2018-2023)
9.2 Japan Human Rabies Immunoglobulin (IM) Sales Breakdown by Type
9.2.1 Japan Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2018-2023)
9.2.2 Japan Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2024-2029)
9.3 Japan Human Rabies Immunoglobulin (IM) Sales Breakdown by Application
9.3.1 Japan Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2018-2023)
9.3.2 Japan Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2024-2029)
10 Southeast Asia Human Rabies Immunoglobulin (IM) 麻豆原创 Facts & Figures
10.1 Southeast Asia Human Rabies Immunoglobulin (IM) Sales by Company
10.1.1 Southeast Asia Human Rabies Immunoglobulin (IM) Sales by Company (2018-2023)
10.1.2 Southeast Asia Human Rabies Immunoglobulin (IM) Revenue by Company (2018-2023)
10.2 Southeast Asia Human Rabies Immunoglobulin (IM) Sales Breakdown by Type
10.2.1 Southeast Asia Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2018-2023)
10.2.2 Southeast Asia Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2024-2029)
10.3 Southeast Asia Human Rabies Immunoglobulin (IM) Sales Breakdown by Application
10.3.1 Southeast Asia Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2018-2023)
10.3.2 Southeast Asia Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2024-2029)
11 India Human Rabies Immunoglobulin (IM) 麻豆原创 Facts & Figures
11.1 India Human Rabies Immunoglobulin (IM) Sales by Company
11.1.1 India Human Rabies Immunoglobulin (IM) Sales by Company (2018-2023)
11.1.2 India Human Rabies Immunoglobulin (IM) Revenue by Company (2018-2023)
11.2 India Human Rabies Immunoglobulin (IM) Sales Breakdown by Type
11.2.1 India Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2018-2023)
11.2.2 India Human Rabies Immunoglobulin (IM) Sales Breakdown by Type (2024-2029)
11.3 India Human Rabies Immunoglobulin (IM) Sales Breakdown by Application
11.3.1 India Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2018-2023)
11.3.2 India Human Rabies Immunoglobulin (IM) Sales Breakdown by Application (2024-2029)
12 Company Profiles and Key Figures in Human Rabies Immunoglobulin (IM) Business
12.1 CSL Behring
12.1.1 CSL Behring Corporation Information
12.1.2 CSL Behring Business Overview
12.1.3 CSL Behring Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2018-2023)
12.1.4 CSL Behring Human Rabies Immunoglobulin (IM) Products Offered
12.1.5 CSL Behring Recent Development
12.2 Grifols
12.2.1 Grifols Corporation Information
12.2.2 Grifols Business Overview
12.2.3 Grifols Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2018-2023)
12.2.4 Grifols Human Rabies Immunoglobulin (IM) Products Offered
12.2.5 Grifols Recent Development
12.3 Sanofi
12.3.1 Sanofi Corporation Information
12.3.2 Sanofi Business Overview
12.3.3 Sanofi Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2018-2023)
12.3.4 Sanofi Human Rabies Immunoglobulin (IM) Products Offered
12.3.5 Sanofi Recent Development
12.4 Sichuan Yuanda Shuyang
12.4.1 Sichuan Yuanda Shuyang Corporation Information
12.4.2 Sichuan Yuanda Shuyang Business Overview
12.4.3 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2018-2023)
12.4.4 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Products Offered
12.4.5 Sichuan Yuanda Shuyang Recent Development
12.5 CNBG
12.5.1 CNBG Corporation Information
12.5.2 CNBG Business Overview
12.5.3 CNBG Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2018-2023)
12.5.4 CNBG Human Rabies Immunoglobulin (IM) Products Offered
12.5.5 CNBG Recent Development
12.6 Kamada
12.6.1 Kamada Corporation Information
12.6.2 Kamada Business Overview
12.6.3 Kamada Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2018-2023)
12.6.4 Kamada Human Rabies Immunoglobulin (IM) Products Offered
12.6.5 Kamada Recent Development
12.7 CBPO
12.7.1 CBPO Corporation Information
12.7.2 CBPO Business Overview
12.7.3 CBPO Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2018-2023)
12.7.4 CBPO Human Rabies Immunoglobulin (IM) Products Offered
12.7.5 CBPO Recent Development
12.8 Shuanglin Bio
12.8.1 Shuanglin Bio Corporation Information
12.8.2 Shuanglin Bio Business Overview
12.8.3 Shuanglin Bio Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2018-2023)
12.8.4 Shuanglin Bio Human Rabies Immunoglobulin (IM) Products Offered
12.8.5 Shuanglin Bio Recent Development
12.9 Weiguang Bio
12.9.1 Weiguang Bio Corporation Information
12.9.2 Weiguang Bio Business Overview
12.9.3 Weiguang Bio Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2018-2023)
12.9.4 Weiguang Bio Human Rabies Immunoglobulin (IM) Products Offered
12.9.5 Weiguang Bio Recent Development
12.10 Shanghai RAAS
12.10.1 Shanghai RAAS Corporation Information
12.10.2 Shanghai RAAS Business Overview
12.10.3 Shanghai RAAS Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2018-2023)
12.10.4 Shanghai RAAS Human Rabies Immunoglobulin (IM) Products Offered
12.10.5 Shanghai RAAS Recent Development
12.11 Bharat Serum
12.11.1 Bharat Serum Corporation Information
12.11.2 Bharat Serum Business Overview
12.11.3 Bharat Serum Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2018-2023)
12.11.4 Bharat Serum Human Rabies Immunoglobulin (IM) Products Offered
12.11.5 Bharat Serum Recent Development
12.12 VINS
12.12.1 VINS Corporation Information
12.12.2 VINS Business Overview
12.12.3 VINS Human Rabies Immunoglobulin (IM) Sales, Revenue and Gross Margin (2018-2023)
12.12.4 VINS Human Rabies Immunoglobulin (IM) Products Offered
12.12.5 VINS Recent Development
13 Human Rabies Immunoglobulin (IM) Manufacturing Cost Analysis
13.1 Human Rabies Immunoglobulin (IM) Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Human Rabies Immunoglobulin (IM)
13.4 Human Rabies Immunoglobulin (IM) Industrial Chain Analysis
14 麻豆原创ing Channel, Distributors and Customers
14.1 麻豆原创ing Channel
14.2 Human Rabies Immunoglobulin (IM) Distributors List
14.3 Human Rabies Immunoglobulin (IM) Customers
15 麻豆原创 Dynamics
15.1 Human Rabies Immunoglobulin (IM) Industry Trends
15.2 Human Rabies Immunoglobulin (IM) 麻豆原创 Drivers
15.3 Human Rabies Immunoglobulin (IM) 麻豆原创 Challenges
15.4 Human Rabies Immunoglobulin (IM) 麻豆原创 Restraints
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

Companies Mentioned:

CSL Behring
Grifols
Sanofi
Sichuan Yuanda Shuyang
CNBG
Kamada
CBPO
Shuanglin Bio
Weiguang Bio
Shanghai RAAS
Bharat Serum
VINS

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.